Nanoreagents Against the Blood-Testis Barrier: A Strategy for Diagnosing and Treating Male Reproductive System Diseases
Abstract
Male reproductive health represents a critical yet challenging area of medical science, where conventional diagnostics and therapies are often limited by physiological barriers-particularly the blood-testis barrier (BTB)-and the complex etiology of disorders such as infertility, prostate cancer, and erectile dysfunction. In recent years, nanoreagents has emerged as a transformative tool, enabling unprecedented advances in drug delivery, imaging, and therapeutic precision. This review systematically examines the application of diverse nanomaterials-including metal nanoparticles, lipid-based systems, polymeric carriers, and natural derivatives such as nanobodies, extracellular vesicles, and cell membrane-coated nanoparticles-in the context of male reproductive medicine. These platforms facilitate targeted drug delivery across the BTB, enhance local drug bioavailability, minimize systemic toxicity, and support sustained release profiles. In diagnostic imaging, nanotechnology augments modalities such as MRI, PET, and photoacoustic imaging. Furthermore, natural biomaterials offer biocompatible and immunologically inert strategies for drug encapsulation and targeted transport, improving both efficacy and safety. Despite these promising developments, challenges remain in standardization, long-term biosafety, and scalable synthesis. Nevertheless, the integration of nanotechnology in male reproductive health is poised to redefine treatment paradigms, offering personalized, efficient,…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.